Bladder cancer study investigates why some patients miss out on new drug combo
NCT ID NCT07339878
First seen Jan 14, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study looks at 50 adults with metastatic bladder cancer who started first-line treatment after October 2024. Researchers want to understand why some patients receive platinum-based chemotherapy instead of the newer Enfortumab Vedotin plus Pembrolizumab combination. The goal is to describe patient characteristics and reasons behind treatment choices, helping to improve future care decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Service Oncologie Médicale - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.